ASCO-GI 2021: Pembrolizumab Promising for Previously Untreated Advanced Hepatocellular Carcinoma
Phase II data from cohort 2 of KEYNOTE 224 reveals durable antitumor activity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.